> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tetra Discovery Gains IND OK for Fragile X Study
- URL: https://www.fdaweb.com/tetra-discovery-gains-ind-ok-for-fragile-x-study/
- Published: 2018-03-16T12:00:00.000Z
- Updated: 2026-09-14T23:53:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140999

FDA has approved a Tetra Discovery Partners IND for BPN14770, a novel, selective small molecule inhibitor of the phosphodiesterase type-4D enzyme. The company says its research suggests the drug may be useful in the treating Fragile X Syndrome and possibly other autism spectrum disorders. Tetra plans to initiate a U.S. Phase 2 trial in adults with Fragile X Syndrome the second quarter. The company is also developing BPN14770 for treating memory cognitive problems associated with Alzheimer’s disease.